MetaCap

Adagene (ADAG) vs MacroGenics (MGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MacroGenics (MGNX) has outperformed Adagene (ADAG) over the past year, gaining 40.0% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -89.6% for MGNX. MacroGenics is the larger company by market cap ($125.3 million vs $118.2 million), about 1.1 times the size, while Adagene is growing revenue faster (+7332.8% vs -0.3%).

MacroGenics converts more of its revenue into profit, with a net margin of -49.9% versus -229.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADAG-2.22%MGNX+40.00%
+260%+115%-31%
Nov 21, 20251 yearNov 20, 2026
ADAG-81.97%MGNX-89.43%
+8%-46%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADAG versus MGNX key metrics
MetricADAGMGNX
Share price$1.76$1.96
Market cap$118.17M$125.26M
1-day change-12.44%-1.01%
YTD return-6.88%+21.74%
1-year return-2.22%+40.00%
5-year return-79.75%-89.56%
EPS (TTM)$-0.37$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.67M$149.50M
Revenue growth (YoY)+7332.76%-0.31%
Net income (latest FY)$-17.61M$-74.62M
Gross margin—100.00%
Operating margin-279.48%-48.72%
Net margin-229.56%-49.91%
52-week high$4.85$5.08
52-week low$1.27$1.32
Distance from 52-week high-63.71%-61.42%
Analyst consensusnonebuy
Avg. price target upside+463.07%+308.16%
Average volume348.81K747.02K
Shares outstanding67.14M63.91M
Employees128293
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MGNX has outperformed ADAG by 42.2 percentage points over the past year.
  • MacroGenics is more profitable, keeping -49.9 cents of every revenue dollar as net income versus -229.6 cents for Adagene.
  • Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -0.31%).

About Adagene

ADAG stock →

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

About MacroGenics

MGNX stock →

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.

Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees

ADAG vs MGNX FAQ

Which is bigger, Adagene or MacroGenics?

MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $118.17M for Adagene (ADAG).

Which stock has performed better over the past year, ADAG or MGNX?

MGNX returned +40.00% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.

Are Adagene and MacroGenics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons